Nuclear Pharma Breakthroughs, Snack Profit Surge Define Hong Kong's Niche Stock Momentum

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In Hong Kong's overlooked small-cap segment, quiet transformations are underway. China Isotope (1763.HK) has cleared two critical hurdles: its 50mg urea breath test kit received NMPA approval for 幽门螺杆菌 diagnosis, while subsidiary CNNC-HT's Lu-177 raw material DMF activation with FDA opens US market pathways. Snack producer TS Wonders (1767.HK) stunned markets with 51.8% net profit growth on 8.9% revenue increase, driven by nut segment expansion.

Retail sector shows contrasting trajectories. Gome Retail (0493.HK) narrowed losses by 76.67% YoY despite 40.74% revenue drop, as strategic shift to asset-light model gains traction. Hang Lung Group (0010.HK) signaled confidence through selective share acquisitions in premium mall portfolio.

Healthcare and consumer plays reveal mixed signals. Dental chain Dazhong Oral (2651.HK) executed 10:2 bonus issue amid significant shareholding restructuring, while apparel OEM Ying Mei (2368.HK) maintained dividend payout despite 20.1% profit decline. Tea retailer Ying Ji Group (8241.HK) appointed new CFO during three-year revenue slump, and Fu Yu Holdings (8269.HK) saw consumer goods trade collapse 22.59% though financial education segment held steady. Hong Kong Ferry (0050.HK) maintained ultra-low volatility with diversified business mix.

These developments, though scattered across sectors, collectively suggest pockets of resilience in Hong Kong's niche stock universe.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.